Stage IVB endometrial cancer: clinical course and survival of patients with single and multiple metastases

Objective: Metastatic endometrial cancer (EC) at initial presentation is a rare disease. The present aim was to evaluate prognostic factors and overall survival in patients diagnosed with metastatic EC. Study Design: Using data from the Geneva Cancer Registry, the authors included all patients diagnosed with Stage IVB EC from 1980-2007. Estimates of survival were calculated using the Kaplan-Meier method and compared using the log-rank test. Results: A total of 38 patients were identified. The most frequent metastases were peritoneal or pleural carcinomatosis (66%, n=25) and hematogenous metastases (53%, n=20). Five-year survival rate was 5.7% (95% confidence interval: 0.0 - 13.3), and median survival was 7.6 months. Survival of patients with a single metastasis at the time of diagnosis was longer than for patients with multiple metastases (16 versus two months, respectively; p < 0.001). Conclusion: Metastatic EC is rare disease with very poor prognosis particularly for patients with multiple site metastases.

Advanced endometrial cancer; Metastatic endometrial cancer; Stage IVB endometrial cancer.

[1] Johann S., Santi A., Guenthert A., Loessl K., Aebi S., Mueller M.: “Car-cinome de l’endomètre”. Forum Med. Suisse, 2010, 10, 129.

[2] Arnold J., Charters D., Perrin L.: “Prolonged survival time following initial presentation with bony metastasis in stage IVb endometrial car-cinoma”. Aust. N Z J Obstet. Gynaecol., 2003, 43, 239.

[3] Eto T., Saito T., K”asamatsu T., Nakanishi T., Yokota H., Satoh T., et al.: Clinicopathological prognostic factors and the role of cytoreduction in surgical stage IVb endometrial cancer: a retrospective multi-institutional analysis of 248 patients in Japan”. Gynecol. Oncol., 2012, 127, 338.

[4] Colombo N., Preti E., Landoni F., Carinelli S., Colombo A., Marini C., et al.: “Endometrial cancer: ESMO Clinical Practice Guidelines for di-agnosis, treatment and follow-up”. Ann. Oncol., 2011, 22, 35.

[5] Bouchardy C., Neyroud-Caspar I., Keller Mighali J., Usel M.: “Le can-cer a Genève - Incidence, mortalite, survie, prévalence, 2003-2006”. Registre genevois des tumeurs, 2009.

[6] Goff B.A., Goodman A., Muntz H.G., Fuller A.F., Jr., Nikrui N., Rice L.W.: “Surgical stage IV endometrial carcinoma: a study of 47 cases”. Gynecol. Oncol., 1994, 52, 237.

[7] Landrum L.M., Moore K.N., Myers T.K., Lanneau G.S. Jr., McMeekin D.S., Walker J.L., Gold M.A.: “Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar out-comes? A case-control analysis”. Gynecol. Oncol., 2009, 112, 337.

[8] Bristow R.E., Zerbe M.J., Rosenshein N.B., Grumbine F.C., Montz F.J.: “Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival”. Gynecol. Oncol., 2000, 78, 85.

[9] Ueda Y., Enomoto T., Miyatake T., Egawa-Takata T., Ugaki H., Yoshino K., et al.: “Endometrial carcinoma with extra-abdominal metastasis: improved prognosis following , ytoreductive surgery”. Ann. Surg. Oncol., 2010, 17, 1111.

[10] Creasman W.T., Odicino F., Maisonneuve P., Quinn M.A., Beller U., Benedet J.L., et al.: “Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer”. Int. J. Gynaecol. Obstet., 2006, 95, S105.

[11] Cook A.M., Lodge N. and Blake P.: “Stage IV endometrial carcinoma: a 10 year review of patients”. Br. J. Radiol., 1999, 72, 485.

[12] Ayhan A., Taskiran C., Celik C., Yuce K. and Kucukali T.: “The influ-ence of cytoreductive surgery on survival and morbidity in stage IVB endometrial cancer”. Int. J. Gynecol. Cancer, 2002, 12, 448.

[13] Numazaki R., Miyagi E., Konnai K., Ikeda M., Yamamoto A., Onose R., et al.: “Analysis of stage IVB endometrial carcinoma patients with distant metastasis: a review of prognoses in 55 patients”. Int. J. Clin. Oncol., 2009, 14, 344.

[14] Khan S.A., Stewart A.K. and Morrow M.: “Does aggressive local ther-apy improve survival in metastatic breast cancer?” Surgery, 2002, 132, 620.

[15] Babiera G.V., Rao R., Feng L., Meric-Bernstam F., Kuerer H.M., Sin-gletary S.E., et al.: “Effect of primary tumor extirpation in breast can-cer patients who present with stage IV disease and an intact primary tumor”. Ann. Surg. Oncol., 2006, 13, 776.

[16] Rapiti E., Verkooijen H.M., Vlastos G., Fioretta G., Neyroud-Caspar I., Sappino A.P., et al.: “Complete excision of primary breast tumor im-proves survival of patients with metastatic breast cancer at diagnosis”. J. Clin. Oncol., 2006, 24, 2743.

[17] Fields R.C., Jeffe D.B., Trinkaus K., Zhang Q., Arthur C., Aft R., et al.: “Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer after con-trolling for site of metastasis”. Ann. Surg. Oncol., 2007, 14, 3345.

[18] Fields R.C., Margenthaler J.A.: “Surgical resection of the primary tumor in stage IV breast cancer patients: is a randomized, controlled trial imperative or too costly?” J. Surg. Oncol., 2009, 99, 85.